MONTREAL, Sept. 4 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that Finnish Regulatory Authorities have been the first one to grant approval to initiate a Phase 3 clinical study with Fentanyl TAIFUN(R). Further approvals are expected in the near future.
